Apollomics Statistics
Total Valuation
Apollomics has a market cap or net worth of $6.27 million. The enterprise value is -$2.55 million.
Important Dates
The last earnings date was Thursday, April 3, 2025, after market close.
| Earnings Date | Apr 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Apollomics has 1.10 million shares outstanding. The number of shares has increased by 37.10% in one year.
| Current Share Class | 1.10M |
| Shares Outstanding | 1.10M |
| Shares Change (YoY) | +37.10% |
| Shares Change (QoQ) | +17.62% |
| Owned by Insiders (%) | 20.75% |
| Owned by Institutions (%) | 0.07% |
| Float | 773,103 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 29.26 |
| Forward PS | n/a |
| PB Ratio | 1.29 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.39 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -229.76 |
Financial Efficiency
Return on equity (ROE) is -233.67% and return on invested capital (ROIC) is -99.39%.
| Return on Equity (ROE) | -233.67% |
| Return on Assets (ROA) | -75.07% |
| Return on Invested Capital (ROIC) | -99.39% |
| Return on Capital Employed (ROCE) | -721.65% |
| Revenue Per Employee | $15,231 |
| Profits Per Employee | -$4.14M |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Apollomics has paid $259,000 in taxes.
| Income Tax | 259,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -86.71% in the last 52 weeks. The beta is 0.92, so Apollomics's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -86.71% |
| 50-Day Moving Average | 6.84 |
| 200-Day Moving Average | 10.58 |
| Relative Strength Index (RSI) | 40.11 |
| Average Volume (20 Days) | 23,920 |
Short Selling Information
The latest short interest is 12,760, so 1.16% of the outstanding shares have been sold short.
| Short Interest | 12,760 |
| Short Previous Month | 2,884 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 1.65% |
| Short Ratio (days to cover) | 0.26 |
Income Statement
In the last 12 months, Apollomics had revenue of $198,000 and -$53.86 million in losses. Loss per share was -$52.80.
| Revenue | 198,000 |
| Gross Profit | 198,000 |
| Operating Income | -41.13M |
| Pretax Income | -172.59M |
| Net Income | -53.86M |
| EBITDA | -41.06M |
| EBIT | -41.13M |
| Loss Per Share | -$52.80 |
Full Income StatementBalance Sheet
The company has $9.78 million in cash and $966,000 in debt, giving a net cash position of $8.81 million or $7.99 per share.
| Cash & Cash Equivalents | 9.78M |
| Total Debt | 966,000 |
| Net Cash | 8.81M |
| Net Cash Per Share | $7.99 |
| Equity (Book Value) | 4.86M |
| Book Value Per Share | 4.41 |
| Working Capital | 2.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.74 million and capital expenditures -$24,000, giving a free cash flow of -$28.77 million.
| Operating Cash Flow | -28.74M |
| Capital Expenditures | -24,000 |
| Free Cash Flow | -28.77M |
| FCF Per Share | -$26.07 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -20,771.21% |
| Pretax Margin | -27,070.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Apollomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.10% |
| Shareholder Yield | -37.10% |
| Earnings Yield | -859.39% |
| FCF Yield | -459.02% |
Analyst Forecast
The average price target for Apollomics is $200.00, which is 3,542.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $200.00 |
| Price Target Difference | 3,542.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on November 25, 2024. It was a reverse split with a ratio of 0.01:1.
| Last Split Date | Nov 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01:1 |
Scores
Apollomics has an Altman Z-Score of -82.58 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -82.58 |
| Piotroski F-Score | 1 |